gsk-256066
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2006 (NCT00377728)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 4BINHIBITOR
PDE4B inhibitor
- Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cccc(Nc2c(C(N)=O)cnc3c(C)cc(S(=O)(=O)c4cccc(C(=O)N(C)C)c4)cc23)c1- Mol. weight
- 518.6 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL570015 ↗
Also known as
- 6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide
- gsk256066
- gsk256066
- gsk256066
- gsk 256066
- gsk-256066
- gsk-256066
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00612118 | Phase 2 | Feb 1, 2008 | GlaxoSmithKline |
| NCT00612820 | Phase 2 | Jan 1, 2008 | GlaxoSmithKline |
| NCT00549744 | Phase 2 | Nov 1, 2007 | GlaxoSmithKline |
| NCT00549679 | Phase 2 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00515268 | Phase 1 | Sep 1, 2007 | GlaxoSmithKline |
| NCT00464568 | Phase 2 | Mar 1, 2007 | GlaxoSmithKline |
| NCT00430157 | Phase 2 | Jan 1, 2007 | GlaxoSmithKline |
| NCT00380354 | Phase 2 | Sep 1, 2006 | GlaxoSmithKline |
| NCT00445510 | Phase 2 | Jun 1, 2006 | GlaxoSmithKline |
| NCT00377728 | Phase 2 | Mar 1, 2006 | GlaxoSmithKline |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 2 | 2006 |
1 organizations
Page 1 / 1